Ioana and you, good Thank everyone. afternoon
last outlined our number stage particularly complexity General to meant Chief plan, management in our and undisputable year, new including affiliate connection Development. cell large most this focusing you plan on call team, Counsel of our field reposition changes BioTime with Business first business, Officer, an made a of the of That reducing Chief of know on new our just President the leader as and to clinical I of of quarterly As my this a therapy. our week Medical a In Vice pipeline. Financial Officer, we also companies hiring
relocating San We Diego. of headquarters are California north also our Carlsbad, just corporate to
With to we plan Therapeutics, investors R&D from only chose we reason GMP We in Lineage also manufacturing these makes gives different facility structure of and name. does retain it felt important and but describing fresh our business. management to look team further better the that functions also elected we our Bay and sense ago, because Israel. and was Cell space take so to year changes in at other Carlsbad, to a now update audiences the place, is what profoundly in company relocate a our office X our do, but a our Area to what We to our job
in relocation ticker, the August be the with shareholders will in You which the change, last and Charlie, letter that a effective name which under name also our XXXX. Please week Monday, our trading on the or X-ray, read as connection available change more about provided for and I website. can XX, Tango, Lima, new note reasons to is LCTX of
which better not believe that focus complete, job doing our AMD intellectual valuable will no as development we communicating but of dry quarterly these injury treatments the and the in will organizational leader with our as there manufacturing physician of property for well increasingly of our highly treatments as progress a expertise our course we FDA highlighting our value into transform the for Lineage on financials. calls these make of physicians the steps also assets, make company. We assets largely spinal only are with and approved With therapeutic the progress a of our cord clinical and
clinical into move updates. now program the will I
cells we program, As operations to weeks in first we data sub-retinal the administered with delivery will the anatomical a engrafted that The without clinical of retinotomy. offices. from have RPE to our we clinical the are centralized California were this first acuity. tears route now in to unexpected and in This are month, access good There no assess be uses subject our of dry announce providing was our being and months, in or visual the whether and suprachoroidal sub-retinal they gain any last Orbit with as our way which this and patient AMD Beginning for growth or terms of baseline punctures. as suspension looks case and no OpRegen, all space collecting GA reminder, success. coming well. dry visual the vitrectomy successfully system whether cells a I successfully benefit did cells The to am procedure AMD need retina to RPE using was world’s administered complications. In a pleased the recovered patient it
our After assessed enrollment dosed dosed introduced now and new the by the but patient and Safety same a window. with attention for vial treatment off-the-shelf promising also it a aspects be reflecting which narrow in the literally therapeutic the program will have to more these At of X be far will OpRegen year we un-inject This our will United by a immediately cells we commercial site therapy, enrolling by a All dose this at desirable new device. States until before we in clinical the improvement, a is to the Clearly, within and saw improvement and another Orbit that and developed. time the of minor a formulation both the OpRegen day end. allows candidate. transport surgeon a Thaw-and-Inject least we XX-day patients dosed cells this to sounds commercially complete an subjects Orbit, full we of time be expect we we third-party this and another eligible review and the those surgical to of patients like avoid Independent Committee, follow-up continue to of characteristic to preparation enroll
award grant new we program. of their support IIA’s announced that additional financial provides of This R&D development confidence $X.X the the Innovation grant May, of approximately in indicative for appreciate grant the our the the In believe of continued from million this is and Authority. OpRegen Israel OpRegen. We funding
Our us also year of million total meaningful the form our endorsement to-date. grant vision tells is a in OpRegen believes vision for in to to a to $X.X our separate from initiative SBIR that restoration $XXX,XXX the progress received third of program. program, data from This which and us award animal generate our direct award additional a grant NIH substantial a we X restoration is Phase supporting made
accepted this vision recent Meeting Our recently for and was fall. at will the work Society publication at for advances in restoration be Nueroscience presented in talk Chicago more the podium
a effective individuals, is despite no reminder, millions dry As FDA there of for approved AMD. therapy
is of responsible developing and even oxidative the to or One community targets the of the stress, the target, the resulting know photoreceptors. is main the targets it scientific to yet challenges and RPE genetic doesn’t inflammation, treatments cells that which for combinations of dry deficiencies damage of is for what XXXs loss in potential AMD of
questions the these cell by receive to approach new one. a with entire potential brand and dead replacing ends Our
there only Our our original this expect are we the cause way. AMD approach. value indifferent the thus lastly, companies less also to to subjective with a of segmentation And to the of in increasing means market commercial be of competing handful potential us
but early, are the we are coming you they encouraging updates with data this meeting October. up Our notably at further forward to and providing look quite most AAO
into this our XX% their program the program, costs. return before month. needed sure their of project. and Asterias OPCX to capabilities on of we slowing full-time a manufacturing I that fully stepped OPCX we transferred had explain a have overlapping cord am Asterias from there this our is we company this injury, the without of Moving spinal to number want Israeli retain our an will of point, where next to and to the we shoes to because program area it noticeably from essentially team successfully from facility only end that just this We related exited we make And it manufacturing employee have facility the in be awareness to clinic by business, to shedding significant AMD can development for because progress. sense Asterias our program while this Freemont process in with Israel broad because pace of employee its ongoing so single to is I entire the success of next with needed the enhancements not deploy our complete had
identification, the introduce site which it take can over year. process the need. approach we making statistics, there address that clinical we commercial bring setup because the the to components is to received evidence even has are In we expect medical And to comparative these study to course clinical we program improvements preparation and greatly which conduct purity scale more study, the specific, ability to process OPCX be designation, discuss other potential be to will to of delivery the another design we trial, have both partner means of manufacturing next increase the protocol which period we Then our RMAT plan value will this and program. meantime, of FDA to and related this additional this this improvements next To activities possible, We plan has begin in the extent believe improvements an will successful so outcome. readiness of indicating year. for preliminary the key that the are unmet will for the
to superior an to antigen, using immune dendritic vaccine back to are the mount cell in instruct with but cells treatment elevated fact, This suspect largely maybe checkpoint absorb response to those our sides, compared our this patients. argument is that aware are cancer treatment, UK we cell against tolerability patients cancer from VACX to whether enhances lung cancer in an to a that our and destruction, inhibitor immune suggested to to on T-cells compelling measure develop cell while Research to a everyone conducting two our best of T-cell data to also clinical call our more our antigen. is either combine Published of currently will have non-small to demonstrate the makes Cancer trial to safety our susceptible but attack tumor on study believe dendritic and vaccine, checkpoint cells. alone. we asset inhibitor activity cancer response we a able outcomes If I vaccine is Moving we a dendritic
today’s of on believe in share we And screening supports we we emerging literature, not Birmingham call, from our of do oncology to would site and while take data note CDX dendritic increasingly, the the the to we responses. folks use which and at to are have CDA cells stimulate positive immune meantime actively program the subjects positive invite
the more around we the We year the to also about assays. end expect say program of immunogenicity the this from to have data after perceive
stay please So tuned.
As application a Mark CE item last will final that its clinical our and of you update, course this is going. year for for still recall on Renevia review we submitted
outcome we provide a we BSI items of guidance We as process We back, do ago. unsatisfying time, and as can persistently weeks all review substantial we for to satisfaction can the receiving we every inform that have than an hear more open inquired we all this completed. because and you many is of this, there promptly it. notified when any updates that BSI. BSI, of us, other Unfortunately, additional is decisions we but clear exists to on are to have can’t meaningful answered that over closed course body, substantive except expect or the for from promptly told definitive our were no will guidance wait at control Since it’s have be backlog as for question little to of without to any to
to over for and things to this I discuss some our additional year. financials now hand have plans we review Brandi will
